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White Fat Progenitor Cells Reside
in the Adipose Vasculature
Wei Tang,1 Daniel Zeve,1 Jae Myoung Suh,1 Darko Bosnakovski,1 Michael Kyba,1
Robert E. Hammer,2 Michelle D. Tallquist,3 Jonathan M. Graff1,3,4*
White adipose (fat) tissues regulate metabolism, reproduction, and life span. Adipocytes form
throughout life, with the most marked expansion of the lineage occurring during the postnatal
period. Adipocytes develop in coordination with the vasculature, but the identity and location of
white adipocyte progenitor cells in vivo are unknown. We used genetically marked mice to isolate
proliferating and renewing adipogenic progenitors. We found that most adipocytes descend from a
pool of these proliferating progenitors that are already committed, either prenatally or early in
postnatal life. These progenitors reside in the mural cell compartment of the adipose vasculature,
but not in the vasculature of other tissues. Thus, the adipose vasculature appears to function as a
progenitor niche and may provide signals for adipocyte development.
How adipocytes (fat cells) develop is afundamental biological question withimportant ramifications for human health
and disease (1, 2). Little is known about the
identity, localization, or biological characteristics
of endogenous adipocyte progenitors (2). These
progenitors probably reside in the adipose stromal-
vascular fraction (SVF), a heterogeneous mixture
of cells operationally defined by enzymatic dis-
sociation of adipose depots followed by density
separation from adipocytes (1, 3). Peroxisome
proliferator-activated receptor gamma (PPARg),
a central regulator of fat formation, is necessary
and sufficient for adipogenesis (4, 5). Thus, mark-
ing PPARg-expressing cells in vivo might provide
insights into adipose lineage specification.
To mark and perform lineage analyses on
PPARg-expressing cells, we generated PPARg–
tet transactivator (tTA) (6) knock-in mice placing
tTA under the control of the PPARg locus (fig. S1)
(7). We introduced into these PPARg-tTA mice
two additional alleles: (i) a tTA-responsive Cre
allele [tetracycline response element-Cre (TRE-
Cre)] and (ii) an element that indelibly expresses
lacZ in response to the Cre recombinase
(ROSA26-flox-stop-flox-lacZ) (8, 9). With these
genetic manipulations, we thereby created a
PPARg-reporter strain (PPARg-R26R, for PPARg-
Rosa26 reporter) in which the endogenous PPARg
promoter/enhancer induces expression of tTA,
leading to Cre expression and an indelible lacZ
marking of PPARg-expressing cells and all de-
scendants (fig. S1). The PPARg-tTA strain func-
tioned as expected; that is, it was active in
adipose depots and repressed by doxycycline
(Dox), establishing a tool to examine the adipose
lineage (Fig. 1A and figs. S1 and S2).
To capture the rapid and dramatic expan-
sion of the adipose lineage that occurs during
the first postnatal month (1, 10), we Dox-treated
the PPARg-R26R mice, starting at different days
during this crucial window (fig. S3A). We found
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Fig. 1. PPARg-expressing progenitors proliferate and maintain the precursor
pool. (A) PPARg-tTA;TRE-Cre;R26R (PPARg-R26R) or PPARg-tTA;TRE-H2B-GFP
(PPARg-GFP) (bottom panels) mice were treated with or without Dox, either
from embryonic day 0 (E0) to postnatal day 30 (P30) (top row) or from P2 to
P30 (middle and bottom rows), and then inguinal and retroperitoneal white
adipose tissues (IWAT and RWAT, respectively) were excised and examined
for lacZ (blue) or GFP (green) expression. Left panels show equivalent depots
of control mice containing either TRE-Cre;R26R or TRE-H2B-GFP. (B) P30 SV
cells from wild-type (left), PPARg-R26R (middle), and PPARg-GFP (right) WAT
were examined for expression of PPARg (red) with immunocytochemistry (left)
or for reporter expression. (Left) Nuclei were stained with 4´,6´-diamidino-2-
phenylindole (DAPI) (blue). Yellow arrows indicate cells that express PPARg
(purple). (Middle) lacZ (blue) nuclei counterstained with nuclear fast red
(red). (Right) GFP (green) nuclei stained with DAPI (blue). (C) Flow cy-
tometry profiles of SV cells of untreated TRE-H2B-GFP (left) or PPARg-GFP
mice treated without (middle) or with Dox (right) from P2 to P30. The
x axis is GFP fluorescent intensity, and the y axis is phycoerythrin (PE)
channel to help illustrate the distribution of GFP+ cells. (Inset) The x
axis is GFP fluorescent intensity, and the y axis is the cell count of the
GFP+ cells per interval of fluorescent intensity (one unit = 1000). SV cells
from TRE-H2B-GFP mice served as a gating control. (D) SV cells removed
from TRE-Cre;R26R (left) and PPARg-R26R mice treated as indicated were
isolated and stained with X-Gal (blue) and nuclear fast red (red). Dox
treatment did not alter the number or percentage of lacZ+ cells based on
statistical analysis of more than 2000 cells counted in each group. Scale
bars: (A), 2 mm; (B) and (D), 50 mm.

































homogenous lacZ expression in postnatal day
30 (P30) adipose depots that was not apprecia-
bly altered, even when Dox administration began
in the first postnatal days (Fig. 1A and fig. S3).
This surprising result indicated that the vast
majority of P30 adipocytes derived from a pre-
existing pool of PPARg-expressing cells, either
adipocytes already present prenatally/early post-
natally or proliferating precursors. Both inter-
pretations conflict with previous data, however.
The possibility that these cells are pre-formed
adipocytes is incompatible with the prolifera-
tive increase that occurs over this time frame,
whereas the notion that PPARg-expressing cells
are progenitors is inconsistent with cell culture
studies (11, 12). To distinguish between the two
possible interpretations, we examined the Dox-
induced response of another reporter, TRE-H2B-
GFP, that is stable in postmitotic cells but, in
contrast to the indelible lacZ marker, becomes
diluted in proliferating cells after inhibition of
the tet system (13, 14). Dox treatment (P2 to
P30) markedly reduced adipose depot and adipo-
cyte green fluorescent protein (GFP) expression
(Fig. 1A), indicating that PPARg-expressing cells
proliferate. Consistent with these data, ~50% of
adipocytes were labeled by bromodeoxyuridine
(BrdU) when administered between P10 and P30
(fig. S4). The stability of lacZ marking together
with the diminishing GFP expression indicate that
adipose lineage cells, already instructed to express
PPARg prenatally, proliferate and are the major
source of the spurt of adipocyte development ob-
served in the first month of life.
The adipose SVF (fig. S5) is postulated to
contain adipocyte progenitors (1, 15). We there-
fore investigated this location as a possible source
from which the proliferating PPARg-expressing
cells characterized above may originate. We
found that a subset of stromal-vascular (SV) cells
expressed immunocytochemically detectable lev-
els of PPARg, as well as the lacZ and GFP re-
porters (Fig. 1B and fig. S6). These SV resident
PPARg-expressing cells proliferate, as they in-
corporated BrdU after a brief 2-hour chase, even
when the BrdU pulse-chase was initiated after
10 days of Dox pretreatment to ensure that cells
containing both GFP and BrdU expressed GFP be-
fore initiation of the brief BrdU pulse (fig. S7). In
addition, GFP+ SV cells isolated by fluorescence-
activated cell sorting (FACS) had considerable
proliferative capacity (fig. S8). Further support
for the in vivo proliferation of the GFP+ SV cells
derives from flow cytometry profiles showing
a Dox-induced (P2 to P30) decrease in the num-
ber and fluorescent intensity of GFP+ SV cells
(Fig. 1C and fig. S9). Dox did not reduce the
number or percentage of lacZ+ SV cells, indica-
ting that a pool of PPARg-expressing cells remains
in the SV compartment (Fig. 1D). Together these
data indicate that the SV compartment of adipose
depots contains PPARg-expressing cells that di-
vide, are mobilized from and also repopulate the
SVF, and behave as an amplifying population that
contributes to the adipocyte lineage.
Fig. 2. PPARg-expressing SV cells are adipogenic and have a uniquemolecular signature. (A) GFP– and GFP+
SV cells from PPARg-GFPmice were sorted, plated, cultured to confluence, and insulin-stimulated adipogenesis
was examined with the lipid-specific stain Oil Red O (red). (B) Sorted GFP+ SV cells were cultured in media or
media supplemented with insulin and then stained with Nile red, a lipid-specific fluorescent dye, to simul-
taneously visualize fat accumulation and GFP expression. (C) (Left) Quantitative real-time fluorescence poly-
merase chain reaction (QPCR) analysis of the indicated markers in sorted GFP+ cells before (green bars) and
after (blue bars) insulin-stimulated adipogenesis. C/EBPa is an adipogenic transcription factor; leptin, adiponectin
(ADPN), and adipsin are adipokines; and Pref-1 is a preadipocyte marker whose expression inversely correlates
with adipogenesis. (Right) SV cells from P30 PPARg-GFP adipose depots were examined for GFP (green) and
perilipin (an adipocyte marker, red) expression both before (top) and after (bottom) adipogenic induction. Nuclei
were stainedwith DAPI (blue). (D to F) FACS-isolated GFP+ SV cells were implanted into nudemice, and the tissue
that formed after 1monthwas photographedwith bright field [left panel in (D)] and fluorescentmicroscopy [right
panel in (D)] and examined with hematoxylin and eosin (H&E) staining [left panel in (E)], GFP fluorescence and
Nile red staining [right panel in (E)], and GFP fluorescence and perilipin immunochemistry (F). (G) (Left) P30
PPARg-GFP adipose depot SV cells were examined for Sca-1 and GFP expression with flow cytometry. The box
indicates the Sca1+GFP+ double-positive population. (Right) IWAT (adipose, top) and SV cells (bottom) of aP2-GFP
transgenics were analyzed for GFP expression, which was present in adipocytes but not in SV cells. PPARg-GFP
serves as a control. Nuclei were stained with DAPI (blue). (H) QPCR analyses of the indicated markers of FACS-
isolated GFP+ SV cells (green bars) and floated adipocytes (blue bars). (I) GFP– SV cells, GFP+ SV cells, and
adipocytes were subjected to gene-expressionprofiling. Theheatmap illustrates 152genes that differentiateGFP+
SV cells from the other populations. Red depicts a greater-than-or-equal-to twofold increase in gene expression,
whereas green depicts a less-than-or-equal-to twofold decrease in gene expression. Scale bars: (A) to (C), (E), and
right panel, bottom row of (G), 50 mm; (D) and right panel, top row of (G), 2 mm; (F), 20 mm in confocal images.

































We assessed the adipogenic potential (in
vitro and after transplantation) of FACS-isolated
GFP+ SV cells (fig. S10). In culture, the sorted
GFP+SVcells underwent spontaneous and insulin-
stimulated adipogenesis that was enhanced com-
pared with GFP– SV cells (Fig. 2, A and B, and
fig. S11). GFP+ SV adipogenesis mirrored the
gene-expression patterns described for preadipo-
cyte cell line adipogenesis, and the induced adipo-
cytes expressed the perilipin protein with the
appropriate subcellular distribution (Fig. 2C)
(16). Moreover, freshly isolated GFP+ P30 SV
cells transplanted into nude mice led to formation
of an ectopic GFP+ depot, containing lipid-laden
adipocytes that coexpressed GFP and perilipin
(Fig. 2, D to F). Thus these GFP+ SV cells have
the proliferative and adipogenic properties ex-
pected of the endogenous progenitor population.
To characterize the GFP+ SV progenitors
and their relationship to other cells present in
the adipose depot, we assessed cell-surface marker
expression using flow cytometry and FACS (fig.
S10). The majority of GFP+ SV cells expressed
Sca1 and CD34, but not CD105, CD45, TER-
119, or Mac-1 (Fig. 2G and fig. S12). When these
markers were used to positively or negatively
select cells (and independently of the GFP
reporter), we again isolated a subset of SV
cells that generated a GFP+ ectopic adipose depot
after transplantation (fig. S13). Some GFP+ SV
cells could potentially be differentiated adipo-
cytes that had yet to accumulate enough lipid to
float during the density-based SV fractionation
procedure. However, reporters driven by the
promoter/enhancer of aP2 (17), a marker of
adipocytes and a PPARg target gene, displayed
strong expression in adipose depots and adipo-
cytes but not in SV cells, unlike the PPARg
reporters (Fig. 2G and fig. S14). Immunocyto-
chemical analyses also showed that the GFP+
SV cells did not express perilipin, an adipocyte
marker (Fig. 2C). In addition, the FACS-isolated
GFP+ SV cells were molecularly distinct from
adipocytes, expressing higher levels of the pre-
adipocyte marker Pref-1, the adipogenic inhibitor
GATA3, and targets of the anti-adipogenic Wnt
(Wisp2) and Hedgehog (Smo, Gli3) pathways and
much lower levels of numerous adipocyte markers
(e.g., C/EBPa, FAS, leptin, etc.) (Fig. 2H and fig.
S15A). Gene-expression profiles further defined
the GFP+ SV cells as a unique population within
adipose tissues (Fig. 2I). Differentially expressed
genes include developmental transcription factors
(e.g., goosecoid and Twist2), extracellular matrix
genes (e.g., MMP3), anti-angiogenic factors (e.g.,
Stab1), and signaling cascade components (e.g.,
EGFR and FGF10) (fig. S15B). Thus, GFP+ SV
Fig. 3. SVP vessels con-
tain GFP+ precursors that
form adipocytes. (A) SVP
structures from P30 PPARg-
GFP mice were photo-
graphed with light (left)
and fluorescent (right) mi-
croscopy. Arrows indicate
an SV tube. (B) PPARg-GFP
SVP tubes were isolated and
stainedwith the lipid-specific
dye boron-dipyrromethene
(BODIPY), either before cul-
ture (left) or after 3 days cul-
tured on a petri dish in
insulin (right). Arrows indi-
cate an SV tube. (C) PPARg-
GFPSVP tubeswere cultured
in suspension. Formation of
adipocytes that derive from
the GFP+ tubes was assessed
with BODIPY staining (red).
GFP is shown in green. Lipid
droplets were visualized with
confocal microscopy (right).
(D) SVP isolates of P30 PPARg-GFP mice were examined for expression of GFP (green) and the indicated
endothelial (PECAM, red) and mural cell (SMA and NG2, blue) markers. (E) PPARg-GFP SVP vessel was
examined for expression of GFP (green) and the mural cell markers PDGFRb (red) and SMA (blue). Yellow
arrows indicate the position of GFP+ nuclei within mural cells. Scale bars: (A), (B), and left panels of (C), 50
mm; right panels of (C), (D) and (E), 20 mm in confocal images.
Fig. 4. GFP+ cells are present in adipose depot mural cells. (A) P30 PPARg-GFP
WAT was freshly frozen, cryosectioned, and examined with direct fluorescence for
GFP and indirect immunofluorescence for the indicated endothelial (PECAM, red)
and mural cell (SMA, blue; NG2, blue; PDGFRb, red) markers. (B) Cryosection of a
PPARg-GFP adipose depot showing expression of GFP, PDGFRb (red), and SMA
(blue). Yellow arrows indicate some mural cell nuclei that express GFP. (C) Muscle
cryosections and retinal whole mount of PPARg-GFPmice were examined for GFP,
PECAM, and SMA as in (A) and (B). GFP was not expressed in mural cells of these
tissues. (D) RWAT (top, ×5) and IWAT (bottom, ×20) of P30 PDGFRb-Cre;R26R
and SM22-Cre;R26R mice were stained for b-galactosidase expression (blue). (E)
SV cells were isolated from P30 wild-type mice and sorted with a PDGFRb
antibody. (Top) Confluent PDGFRb-negative and -positive cells were cultured in
insulin, and fat formation was assessed with BODIPY (red). (Bottom) PDGFRb-
negative and -positive cells were transplanted into nude mice, and the resultant
tissues were sectioned andH&E stained. (F) Adipose SVF and cells dissociated from
the kidney were sorted with a PDGFRb antibody, and PDGFRb-positive cells were
cultured in the absence (top) or presence (bottom) of TZD. Scale bars: (A) to
(C), 20 mm in confocal images; (D), 1 mm; (E) and (F), 50 mm.

































cells are phenotypically distinct from adipocytes
and other SV cells and have a unique molecular
signature that allows prospective isolation for
transplantation and further lineage analyses.
The local microenvironment (niche) is a
crucial determinant of progenitor fate, function,
and maintenance (18). In part due to the nature
of the SV dissociation and isolation method, the
anatomical location and neighboring cells of the
SVadipocyte precursors are not known. To inves-
tigate the architecture of the SV compartment,
we developed an SV particulate (SVP) isolation
procedure designed to partially maintain the na-
tive SV structure while removing adipocytes that
obscure visualization of the precursor location
(fig. S16). In the SVPs, the majority of GFP+ cells
were arrayed in tubelike structures (Fig. 3A).
Based on inspection and lack of lipid staining,
the GFP+ cells present in freshly isolated tubes
did not contain lipid droplets (Fig. 3, A and B).
Organotypic cultures of SVPs led to formation
of lipid-laden GFP+ adipocytes along the tubes,
indicating that the tube-associated SVP GFP+
cells were adipogenic (Fig. 3, B and C). Because
the SVP tubes resembled blood vessels, we stained
them with antibodies that recognize constituent
cells of the vasculature, including platelet endo-
thelial cell adhesionmolecule (PECAM) and three
mural cell markers (SMA, PDGFRb, and NG2)
(19). The SVP tubes expressed PECAM and
were surrounded by cells that expressed SMA,
PDGFRb, and NG2, indicating that they were
vessels (Fig. 3, D and E). GFP+ SVP cells ex-
pressed thesemural cell markers (Fig. 3, D and E).
The notion that PPARg might be expressed in a
subset of mural cells is noteworthy because cul-
tured mural cells, similar to mesenchymal stem
cells, are multipotent and can be induced to under-
go adipogenesis, chondrogenesis, osteogenesis, and
myogenesis and may provide a progenitor res-
ervoir (19, 20).
To investigate the distribution of the GFP+
progenitors within the mural cell compartment,
we immunohistochemically examined sections of
freshly frozen PPARg-GFP P30 adipose depots
and other organs. In the adipose vasculature, we
again observed colocalization of GFP and mural
cell markers (Fig. 4, A and B). The GFP+ vessels
were of various sizes and disseminated through-
out the depot (Fig. 4A). However, only a subset
of mural cells within a vessel expressed GFP, and
some adipose vessels did not appear to harbor
GFP+ progenitors (fig. S17). Mural cells in other
examined P30 tissues (including skeletal and
cardiac muscles, kidney, retina, pancreas, spleen,
lung, etc.) did not express the GFP reporter (Fig.
4C and fig. S18). In older animals (~6 months),
we detected GFP in some small caliber PECAM-
positive, SMA-negative adult skeletal muscle
vessels (figs. S19 and S20). The majority of
these adult skeletal muscle GFP+ cells expressed
PECAM, and the cells were not adipogenic (fig.
S20). Thus, adipose depots appear to contain a
unique population of progenitors present in the
adipose depot mural cell compartment.
PDGFRb marks mural cells and is required
for their development (19). To explore the pos-
sibility that PDGFRb-expressing cells were part
of the adipocyte lineage, we used b-galactosidase
(X-Gal) to stain adipose depots of P30 mice that
contained both a PDGFRb-Cre transgene (21),
which expresses Cre in mural cells and other
developing cells, and R26R. As a specificity
control, we used SM22-Cre (22), a driver con-
struct expressed in a subset of vascular smooth
muscle cells. In theseCre-mediated lineage studies,
we found that PDGFRb-Cre generated strong and
relatively homogenous lacZ expression throughout
adipose depots in adipocytes and mural cells
(Fig. 4D). In contrast, SM22-Cre did not, although
lacZ was expressed in a distinct subset of adipose
depot vessels (Fig. 4D).
To assess the adipogenic potential of PDGFRb-
expressing mural cells, we isolated PDGFRb-
positive and -negative cells from white adipose
tissues and other organs by FACS, cultured them
in insulin, or transplanted them into nude mice
(fig. S21). In both assays, the adipose depot
PDGFRb+ SV cells had higher (and substantially
more) adipogenic potential than did PDGFRb−
SV cells (Fig. 4E); this adipogenesis was stim-
ulated by thiazolidinediones (TZDs), which are
diabetes drugs that activate PPARg (23) (Fig. 4F).
In contrast, PDGFRb+ cells isolated from other
organs did not display such potential and were
unresponsive to TZDs (Fig. 4F and fig. S22).
Although we could identify sections that con-
tained adipocytes in the non-adipose transplants,
these adipocytes were GFP-negative (in con-
trast to adipocytes present in adipose depot SV
PDGFRb+ transplants) (fig. S22), apparently de-
rived or recruited from host tissues. These data
are consistent with the possibility that adipo-
cyte progenitors reside as adipose depot mural
cells with distinct properties such as adipogenic
potential.
The intertwined epidemics of obesity and
diabetes have led to a public health crisis that
demands an improved understanding of adipocyte
biology (2, 24). Yet the identity of the adipocyte
progenitors and their precise location has remained
elusive. Exploiting genetic reporters, we show that
the pool of murine white adipocyte precursors has
largely been committed prenatally or just after
birth. These precursors divide, maintain the pro-
genitor pool, and produce adipocytes. Some of
these progenitors appear to be mural cells that
reside in the vasculature of adipose tissue; these
results are supported by early electronmicrograph-
ic studies (25, 26). Thus, the adipose vasculature
appears to function as a progenitor niche and may
provide signals for adipocyte development.
Several earlier studies have documented an
interplay between adipose tissue and the vascu-
lature and shown that this interaction provides
possible targets for obesity/diabetes therapies
(27–30). The results described here add a fresh
perspective to this interplay. In addition, they pro-
vide a foundation for further characterization of
the adipose vascular niche and for prospective
isolation of the adipocyte progenitors. Such exper-
iments should help to establish whether inter-
vention in adipose lineage formation can be an
effective therapeutic approach for obesity and
diabetes.
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